Pharmacodynamic target attainment of oral β-lactams for the empiric treatment of acute otitis media in children

Pediatric Drugs

Volumn 10, Issue 5, 2008, Pages 329-335

  Fallon, Renee M ^a,b,c   Kuti, Joseph L ^d   Doern, Gary V ^e   Girotto, Jennifer E ^b,c   Nicolau, David P ^d  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Division of Pediatric Infectious Diseases   (United States)

^d HARTFORD HOSPITAL   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Amoxicillin, pharmacodynamics; Amoxicillin clavulanic acid, pharmacodynamics; Cefpodoxime, pharmacodynamics; Children; Lactams, pharmacodynamics; Lactams, therapeutic use; Otitis media, prevention

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFUROXIME; CEFUROXIME AXETIL;

ACUTE OTITIS MEDIA; ARTICLE; BACTERIUM ISOLATE; CHILD; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHILD; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OTITIS MEDIA; STREPTOCOCCUS PNEUMONIAE;

EID: 50649106846     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810050-00006     Document Type: Article

References (31)

1. American Academy of Pediatrics and American Academy of Family Physicians. Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451-65
2. Berman S. Otitis media in children. N Engl J Med 1995; 332: 1560-5
3. Klein JO. Otitis media. Clin Infect Dis 1994; 19: 823-33
4. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23: 829-33
5. Casey JR, Pichichero ME. Changes in the frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23: 824-8
6. Khan W, Ross S, Rodriguez W, et al. Haemophilus influenzae type b resistant to ampicillin: a report of two cases. JAMA 1974; 229: 298-301
7. Tomeh MO, Starr SE, McGowan JE, et al. Ampicillin-resistant Haemophilus influenzae type B infection. JAMA 1974; 229: 295-7
8. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139-48
9. US Pediatric Surveillance Data 2001-2002. Surveillance Data Inc., Focus Technologies Inc., Plymouth Meeting, PA, USA
10. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004, 65
11. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003; 22 (11): 982-92
12. Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40
13. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22
14. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl. 1: S42-50
15. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th edition. CLSI document M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2007
16. Center for Disease Control and Prevention. Weight-for-age infant growth charts [online]. Available from URL: http://www.cdc.gov/nchs/data/nhanes/ growthcharts/zscore/weageinf.xls [Accessed 2007 Nov 28]
17. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15: 949-54
18. Kearns GL, Abdel-Rahman SM, Jacobs RF, et al. Cefpodoxime pharmacokinetics in children: effect of food. Pediatr Infect Dis J 1998; 17: 799-804
19. Nicolau DP, Sutherland CS, Arguedos A, et al. Pharmacokinetics of cefprozil in plasma and middle ear fluid in children undergoing treatment for acute otitis media. Paediatr Drugs 2007; 9: 119-23
20. Kearns GL, Reed MD, Jacobs RF, et al. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991; 35: 2078-84
21. Ginsburg CM, McCracken GH, Petruska M, et al. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985; 28: 504-7
22. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001; 45 (1): 13-22
23. Marchant CD, Carlin SA, Johnson CE, et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon". J Pediatr 1992; 120: 72-7
24. Klein JO. Microbiological efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J. 1993; 12: 973-5
25. Harrison CJ. Changes in treatment strategies for acute otitis media after full implementation of the pneumococcal seven valent conjugate vaccine. Pediatr Infect Dis J 2003; 22: S120-30
26. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004; 23: 1142-52
27. Arguedas A, Emparanza P, Schwartz RH, et al. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005; 24: 153-61
28. Dagan R, McCracken Jr GH. Flaws in design and conduct of clinical trials in acute otitis media. Pediatr Infect Dis J 2002; 21: 894-902
29. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of β-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther 2005; 27: 1820-30
30. Bradley JS. Pharmacodynamics and the prediction of efficacy in short-course antibiotic therapy: pediatric studies to validate the model. Pharmacotherapy 2005; 25: 159S-64S
31. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program. Paediatr Drugs 2006; 8: 131-8